Related Experiment Video

Updated: May 20, 2026

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
10:44

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Published on: January 31, 2018

Role of PARP inhibitors in cancer biology and therapy

D Davar1, J H Beumer, L Hamieh

  • 1Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

Current Medicinal Chemistry
|July 14, 2012
PubMed

Insights

Poly(ADP-ribose) polymerase (PARP) inhibitors, initially for DNA repair-deficient cancers, are now used in combination therapies and non-malignant diseases. This review details their preclinical and clinical development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Advances in understanding DNA repair mechanisms highlighted poly(ADP-ribose) polymerase (PARP) as a therapeutic target in oncology.
  • PARP inhibitors were initially designed to leverage synthetic lethality in cancers with deficient DNA repair pathways.
  • Expanding knowledge of PARP biology has broadened their application beyond initial indications.

Purpose of the Study:

  • To review the fundamental mechanisms of DNA repair.
  • To provide an overview of the preclinical development of PARP inhibitors.
  • To comprehensively discuss the clinical development and applications of various PARP inhibitors.

Main Methods:

  • Literature review of DNA repair mechanisms.
  • Analysis of preclinical studies on PARP inhibitors.
  • In-depth examination of clinical trial data for PARP inhibitors.

Main Results:

  • Established the role of DNA repair in cancer therapeutic strategies.
  • Demonstrated the preclinical efficacy of PARP inhibitors.
  • Detailed the clinical progression and diverse applications of PARP inhibitors in oncology and other diseases.

Conclusions:

  • PARP inhibitors represent a significant advancement in targeted cancer therapy.
  • Their therapeutic utility extends to combination treatments and non-malignant conditions.
  • Continued research into PARP biology promises further innovation in drug development.

More Related Videos

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging06:44

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Published on: April 28, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...